Clinical Trials Logo

HCC clinical trials

View clinical trials related to HCC.

Filter by:

NCT ID: NCT01871545 Completed - Clinical trials for Hepatocellular Carcinoma

Evaluation of Liver Cancer With Magnetic Resonance Imaging (MRI)

Start date: June 2013
Phase: N/A
Study type: Interventional

The incidence of hepatocellular carcinoma (HCC) has recently increased in the United States. Although imaging plays a major role in HCC screening and staging, the possibility of predicting HCC tumor grade, aggressiveness, angiogenesis and hypoxia with imaging are unmet needs. In addition, new antiangiogenic drugs now available to treat advanced HCC necessitate the use of new imaging criteria beyond size. The investigators would like to develop and validate non-invasive magnetic resonance imaging (MRI) methods based on advanced diffusion-weighted imaging (DWI), MR Elastography, BOLD (blood oxygen level dependent) MRI and perfusion-weighted imaging (PWI, using gadolinium contrast) to be used as non-invasive markers of major histopathologic features of HCC, and to predict and assess early response of HCC to systemic therapy. The investigators also would like to develop quality control tools to improve the quality and decrease variability of quantitative MRI metrics. These techniques combined could represent non-invasive correlates of histologic findings in HCC, could enable individualized therapy, and provide prognosis in patients with HCC.

NCT ID: NCT01470495 Recruiting - HCC Clinical Trials

Combined Treatment of RFA and Sorafenib on Recurrent HCC

REPEAT
Start date: January 2015
Phase: N/A
Study type: Interventional

RFA is a routaine treatment of recurrent HCC. Recently Sorafenib was reported to be a promising drug to treat late stage HCC. But few studies were related with its effectiveness on recurrent HCC. So the investigators hypothesized that combined RFA and Sorafenib might reduce the frequency of recurrence and improve the overall survival and disease free survial.

NCT ID: NCT01387555 Completed - Clinical trials for Hepatocellular Carcinoma

A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib

TRAVERSE
Start date: December 2008
Phase: Phase 2
Study type: Interventional

This study is to determine whether JX-594 (Pexa-Vec) plus best supportive care is more effective in improving survival than best supportive care in patients with advanced Hepatocellular Carcinoma (HCC) who have failed sorafenib.

NCT ID: NCT01356628 Active, not recruiting - Liver Cancer Clinical Trials

A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer

Start date: May 25, 2011
Phase: Phase 2
Study type: Interventional

This is a Phase 2 Study of PD-0332991 in the treatment of patients with Advanced Hepatocellular Carcinoma (HCC), a type of adenocarcinoma and the most common type of liver tumor. PD-0332991 is a compound that stops the tumor cell from entering the Synthesis phase of the cell cycle, therefore stopping DNA multiplication and decreased tumor cell copying.

NCT ID: NCT01265576 Active, not recruiting - HCC Clinical Trials

Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)

Start date: December 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if VT-122 provides a clinical benefit when added to Sorafenib in patients with advanced hepatocellular carcinoma (HCC).